Partners
Research Centres
The Liverpool Hospital Cyclotron Facility is an essential component of the routine radiopharmaceutical manufacturing for the Department of Nuclear Medicine and PET at Liverpool Hospital and the South Western Sydney Local Health District. The facility is a modern well-equipped radiopharmaceutical manufacturing facility built to GMP standards, centred around a GE Healthcare PETtrace 890 Cyclotron. The team comprises of PhD-trained radiopharmaceutical scientists and cyclotron engineers. The LHCF manufactures Fluorine-18 products every weekday ensure the reliable supply of fluorine-18 radiopharmaceuticals to NSW while supporting the research and development activities across NSW. The radiopharmacy at Liverpool Hospital manufactures gallium-68 radiopharmaceuticals for routine and research use.
Visit the SWSLHD Liverpool Hospital - Department of Nuclear Medicine and PET
ANSTO leverages great science to deliver big outcomes. We partner with scientists and engineers and apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment. ANSTO is a leading player in the development and translation of radiopharmaceuticals to improve the detection and diagnosis of disease. ANSTO has the expertise and capabilities to supply radioisotopes and undertake radiochemistry, radiation biology and preclinical imaging studies to develop and evaluate radiopharmaceuticals. This includes the use of new radioisotopes from the OPAL multipurpose reactor.
The Helmholtz-Zentrum Dresden-Rossendorf is a modern large-scale research centre located at the northeastern outskirts of Dresden, Germany. Almost 700 scientists from more than 70 nations conduct cutting-edge research with a
long-term focus in the fields of energy, health and matter, which is funded by the German Federal Government as well as the Free State of Saxony. As a member of the Helmholtz Association of German Research Centres, HZDR has the
mission to deliver solutions to the great challenges of our time including a substantial contribution to a healthy society with novel diagnostic and therapeutic methods in cancer research.
Industry Partners
GlyTherix Ltd is a targeted radiotherapy company with a clinical stage product showing an excellent safety profile in high unmet need cancers. Our antibody, Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.
iPHASE technologies is a world class designer and manufacturer of automated instrumentation for P.E.T. radiochemistry. By using the latest automation technologies coupled together with intelligent design and class leading software interfaces, our instrumentation is built by users for users.
